Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127250071 | 12725007 | 1 | I | 20160717 | 20160908 | 20160908 | PER | US-ASTRAZENECA-2016SE78496 | ASTRAZENECA | 0.00 | M | Y | 87.90000 | KG | 20160908 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127250071 | 12725007 | 1 | PS | BYDUREON | EXENATIDE | 1 | Subcutaneous | FN0081 | 22200 | 2 | MG | /wk | |||||||
| 127250071 | 12725007 | 2 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | Y | AZ150029 | 0 | 10 | UG | SUSPENSION FOR INJECTION IN PRE-FILLED PEN | BID | |||||
| 127250071 | 12725007 | 3 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 127250071 | 12725007 | 4 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 127250071 | 12725007 | 5 | C | LOW DOSE ASPIRIN | ASPIRIN | 1 | Oral | 0 | 81 | MG | QD | ||||||||
| 127250071 | 12725007 | 6 | C | ALLPRAZOLAM | 2 | Oral | 1 MG THREE TIMES A DAY AS NEEDED | 0 | |||||||||||
| 127250071 | 12725007 | 7 | C | ZOLDIPOEM | 2 | Oral | 0 | 10 | MG | QD | |||||||||
| 127250071 | 12725007 | 8 | C | TRAMADOL. | TRAMADOL | 1 | Oral | 50 MG 4 TIMES A DAY AS NEEDED | 0 | ||||||||||
| 127250071 | 12725007 | 9 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 127250071 | 12725007 | 10 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 127250071 | 12725007 | 11 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 500 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127250071 | 12725007 | 1 | Type 2 diabetes mellitus |
| 127250071 | 12725007 | 2 | Type 2 diabetes mellitus |
| 127250071 | 12725007 | 3 | Blood pressure abnormal |
| 127250071 | 12725007 | 4 | Blood cholesterol abnormal |
| 127250071 | 12725007 | 5 | Prophylaxis |
| 127250071 | 12725007 | 6 | Anxiety |
| 127250071 | 12725007 | 7 | Sleep disorder |
| 127250071 | 12725007 | 8 | Fibromyalgia |
| 127250071 | 12725007 | 9 | Gastrooesophageal reflux disease |
| 127250071 | 12725007 | 10 | Gastrooesophageal reflux disease |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127250071 | 12725007 | Injection site mass | |
| 127250071 | 12725007 | Wrong technique in product usage process |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127250071 | 12725007 | 1 | 201512 | 0 | ||
| 127250071 | 12725007 | 2 | 201512 | 0 |